GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » Equity-to-Asset

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Equity-to-Asset : 0.71 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Skystar Bio-Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Sep. 2014 was $122.51 Mil. Skystar Bio-Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2014 was $171.61 Mil. Therefore, Skystar Bio-Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Sep. 2014 was 0.71.

The historical rank and industry rank for Skystar Bio-Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

SKBI's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Equity-to-Asset only.

Skystar Bio-Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co Equity-to-Asset Chart

Skystar Bio-Pharmaceutical Co Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 0.88 0.85 0.83 0.81

Skystar Bio-Pharmaceutical Co Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.81 0.82 0.73 0.71

Competitive Comparison of Skystar Bio-Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skystar Bio-Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's Equity-to-Asset falls into.



Skystar Bio-Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Skystar Bio-Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as

Equity to Asset (A: Dec. 2013 )=Total Stockholders Equity/Total Assets
=110.393/136.223
=0.81

Skystar Bio-Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Sep. 2014 is calculated as

Equity to Asset (Q: Sep. 2014 )=Total Stockholders Equity/Total Assets
=122.505/171.608
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Skystar Bio-Pharmaceutical Co  (GREY:SKBI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Skystar Bio-Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Traded in Other Exchanges
N/A
Address
No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN
Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines